Search

everythinglearnresearchcommunity

for

Search:↓

Topical diazoxide may be a promising hair regrowth treatment, especially for those who don't respond to minoxidil, as it activates potassium channels without needing sulfation. It appears safe for topical use, avoiding systemic effects seen in oral use.

The conversation is about the lack of improvement in hair loss after using Pyrilutamide for 14 weeks, with the original poster unable to use Finasteride due to depression. Replies suggest that Pyrilutamide, like RU58841, may not work for everyone, and a more potent drug is being developed by Kintor.

The conversation discusses using azelaic acid to reduce scalp inflammation while using RU58841 for hair loss. It suggests applying azelaic acid in the morning and RU58841 at night to avoid degradation, while also using dutasteride and minoxidil.

The conversation discusses whether a product recommended by a Portuguese pharmacist is the same as Minoxidil. Treatments mentioned include Minoxidil, Finasteride, and RU58841.

A user trying various treatments for hair loss, such as minoxidil, stemoyxidine, alfatradiol, and microneedling, with plans to add tretinoine and finasteride.

Eucapil/fluridil is discussed as a potential treatment for hair loss, with questions about its effectiveness and why it isn't a primary treatment. Minoxidil, finasteride, and RU58841 are also mentioned as treatments.

The conversation discusses the removal of Breezula phase II 12-month results by Cassiopea and the search for the original data. Concerns were raised about potential negative long-term effects on hair growth, such as androgen receptor upregulation.

User discusses Eucapil for hair loss treatment and asks if it helps with itchy scalp. People share their experiences and results, including maintenance or slight improvement.

A 25-year-old uses oral minoxidil, dutasteride, and a shampoo with minoxidil and ketoconazole for hair loss, experiencing progress and increased body hair. Users discuss the effectiveness of these treatments, with some suggesting that dutasteride is primarily responsible for hair thickening.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

The user is considering adding an anti-androgen, RU58841, to their current hair loss treatment routine due to receding hair. They are also contemplating waiting for Breezula or Pyrilutamide to become more affordable.

A user is experiencing hair thinning and is using a peptide with oleanic acid as a DHT blocker, along with minoxidil, while waiting for topical finasteride. They plan to use a combination of minoxidil, finasteride, dermastamp, ketoconazole, and scalp massages, but are advised to stick to proven treatments like finasteride and minoxidil.

The conversation discusses the use of AlphaInfuse, a micro-infusion system with Panax ginseng and Eclipta prostrata extracts, for hair growth and its comparison to Minoxidil. The original poster seeks personal experiences and evidence of its effectiveness.

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

Potential success with the hair loss treatment Pyrilutamide, and possible group buying opportunities for it along with other treatments such as Finasteride and Minoxidil.

Azelaic acid is considered a strong DHT inhibitor with no reported sexual side effects, making it a potential alternative for those who cannot use finasteride. It can be used with minoxidil, but may cause skin irritation.

Exosome treatment for hair loss is viewed skeptically, with one person calling it a scam. Another suggests sticking with finasteride and minoxidil instead.

Exosome therapy for hair loss is being discussed, with mixed personal experiences and no significant results reported by some users. The treatment is expensive, and users are skeptical about its effectiveness.

Exosome stem cell treatment for hair loss, which is expensive and reportedly effective, but its popularity has declined. The conversation also mentions Minoxidil, finasteride, and RU58841 as treatments.

The conversation discusses finding sources of Dutasteride in Europe for mesotherapy to treat hair loss. It also mentions using Minoxidil, Finasteride, and RU58841 as treatments.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

New hair loss treatments include Breezula, PP405, ET-02, KX-826, GT20029, VDPHL01, and CosmeRNA, with some showing promise in reactivating stem cells and reversing greying. Breezula and VDPHL01 are highlighted as potential add-ons or alternatives to current treatments like finasteride and minoxidil.

The launch of Pyrilutamide as a potential hair loss treatment, with people discussing whether it is better than treatments like finasteride and minoxidil. Some participants have also discussed the risks associated with importing drugs from China.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

The user successfully reduced hair loss using pumpkin seed oil, Nizoral shampoo, and astaxanthin without using minoxidil or finasteride. They observed significant improvement over 12 months and believe the combination of treatments is effective.

The conversation discusses alternatives to 5AR inhibitors for hair loss treatment, suggesting options like minoxidil, KX-826, pyrilutimide, microneedling, and topical bicalutamide. Concerns about side effects and the effectiveness of these treatments are also highlighted.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation is about creating a topical hair loss treatment with B6, zinc, and azelaic acid, which is claimed to inhibit 90% of scalp DHT. One user is skeptical about the effectiveness of this treatment and its comparison to other treatments without side effects.

Discussion on hair loss treatments, focusing on Breezula, with mentions of Minoxidil, finasteride, RU58841, Pyrilutamide, GT20029, and PP405. Breezula's effectiveness is uncertain, with some trials showing minimal regrowth.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.